Case Report: Tuberculosis-Induced Autoimmune Hemolytic Anemia

Seham M. Alebbi Department of Medical Education, Hamad Medical Corporation, Doha, Qatar;

Search for other papers by Seham M. Alebbi in
Current site
Google Scholar
PubMed
Close
,
Aalaa Kambal Clinical Imaging Department, Hamad Medical Corporation, Doha, Qatar;

Search for other papers by Aalaa Kambal in
Current site
Google Scholar
PubMed
Close
,
Hayan Abo Samra Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar;
Histopathology Department, Hamad Medical Corporation, Doha, Qatar;

Search for other papers by Hayan Abo Samra in
Current site
Google Scholar
PubMed
Close
,
Mouhammad Z. Sharaf Eldean Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar;
Histopathology Department, Hamad Medical Corporation, Doha, Qatar;

Search for other papers by Mouhammad Z. Sharaf Eldean in
Current site
Google Scholar
PubMed
Close
,
Shehab Fareed Mohamed Department of Hematology and Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar;

Search for other papers by Shehab Fareed Mohamed in
Current site
Google Scholar
PubMed
Close
, and
Shaikha D. Al-Shokri Department of Medical Education, Hamad Medical Corporation, Doha, Qatar;
Department of Internal Medicine, Case Western Reserve University–MetroHealth Medical Center, Cleveland, Ohio

Search for other papers by Shaikha D. Al-Shokri in
Current site
Google Scholar
PubMed
Close
Restricted access

ABSTRACT.

Tuberculosis (TB) is an infectious disease that affects different organs, causing multiple complications, including hematological sequelae. One of the most common TB-hematological complications is anemia of chronic disease. Very rarely autoimmune hemolytic anemia (AIHA) has been reported as an uncommon manifestation of TB. In this case, we present a female who presented with refractory AIHA, which was attributed to disseminated TB. The patient responded well to steroids, anti-TB medications, and rituximab.

Author Notes

Correspondence to Shaikha D. Al-Shokri, Department of Internal Medicine, Case Western Reserve University–MetroHealth Medical Center, 2500 Metrohealth Dr., Cleveland, OH 44109. E-mail: salshokri@hamad.qa

These authors contributed equally to this work.

Disclosure: This article was approved by Hamad Medical Corporation Medical Research Center. This research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Authors’ addresses: Seham M. Alebbi, Department of Medical Education, Hamad Medical Corporation, Doha, Qatar, E-mail: salebbi@hamad.qa. Aalaa Kambal, Clinical Imaging Department, Hamad Medical Corporation, Doha, Qatar, E-mail: akambal@hamad.qa. Hayan Abo Samra and Mouhammad Z. Sharaf Eldean, Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar, E-mails: hsamra@hamad.qa and meldean@hamad.qa. Shehab Fareed Mohamed, Department of Hematology and Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar, E-mail smohamed22@hamad.qa. Shaikha D. Al-Shokri, Department of Medical Education, Hamad Medical Corporation, Doha, Qatar and Department of Internal Medicine, Case Western Reserve University–MetroHealth Medical Center, Cleveland, Ohio, E-mail: salshokri@hamad.qa.

  • 1.

    Gehrs BC, Friedberg RC, 2002. Autoimmune hemolytic anemia. Am J Hematol 69: 258–271.

  • 2.

    Sève P, Philippe P, Dufour JF, Broussolle C, Michel M, 2008. Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Rev Hematol 1: 189–204.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Coburn RJ, England JM, Samson DM, Walford DM, Blowers R, Chanarin I, Levi AJ, Slavin G, 1973. Tuberculosis and blood disorders. Br J Haematol 25: 793–799.

  • 4.

    Glasser RM, Walker RI, Walker RI, 1970. The significance of hematologic abnormalities in patients with tuberculosis. Arch Intern Med 125: 691–695.

  • 5.

    Cameron SJ, 1974. Tuberculosis and the blood—a special relationship? Tubercle 55: 55–72.

  • 6.

    Berkowitz FE, 1991. Hemolysis and infection: categories and mechanisms of their interrelationship. Rev Infect Dis 13: 1151–1162.

  • 7.

    Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, 2017. The diagnosis and management of primary autoimmune hemolytic anaemia. Br J Haematol 176: 395–411.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Berentsen S, 2020. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol 11: 590.

  • 9.

    Berentsen S, Tjønnfjord GE, 2012. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 26: 107–115.

  • 10.

    Adigun R, Singh R, 2022. Tuberculosis. Tampa, FL: StatPearls Publishing [Internet]. PMID:28722945.

  • 11.

    Rathish D, Siribaddana S, 2018. Tuberculosis-induced autoimmune haemolytic anaemia: a systematic review to find out common clinical presentations, investigation findings and the treatment options. Allergy Asthma Clin Immunol 14: 11.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Shah M, Reed C, 2014. Complications of tuberculosis. Curr Opin Infect Dis 27: 403–410.

  • 13.

    Klein HG, Anstee DJ, 2014. Mollison’s Blood Transfusion in Clinical Medicine, 12th edition. New York, NY: John Wiley & Sons.

  • 14.

    Jäger U et al., 2020. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev 41: 100648.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, 2017. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 177: 208–220.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Petz LD, 1983. Autoimmune hemolytic anemia. Hum Pathol 14: 251–255.

  • 17.

    Dussadee K, Taka Bsc O, Thedsawad Msc A, Wanachiwanawin W, 2010. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thai 93 (Suppl 1): S165–S170.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Garvey B, 2008. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141: 149–169.

  • 19.

    Berentsen S, 2007. Rituximab for the treatment of autoimmune cytopenias. Haematologica 92: 1589–1596.

  • 20.

    Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB, 2005. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90: 1273–1274.

    • PubMed
    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 5608 3302 96
Full Text Views 390 36 0
PDF Downloads 201 36 0
 

 

 

 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save